Moteur de recherche d’entreprises européennes
Financement de l’UE (5 994 176 €) : Preuve de concept clinique par le biais d’une étude randomisée de phase II : une combinaison d’immunothérapie et de radiothérapie ablative stéréotaxique comme … Hor19/12/2016 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Preuve de concept clinique par le biais d’une étude randomisée de phase II : une combinaison d’immunothérapie et de radiothérapie ablative stéréotaxique comme traitement curatif d’un cancer du poumon métastatique limité
IMMUNOSABR is geared towards opening up a new paradigm in treating metastatic cancer by obtaining clinical proof of concept for a novel bi-modal curative treatment strategy. High precision stereotactic ablative radiotherapy (SABR) is combined with immunotherapy to form a powerful synergistic anti-tumour strategy. The approach relies on the direct cytotoxic effect of SABR, the abscopal effect of radiation observed at distance from the irradiated metastatic site(s), and the effect of the tumour-specific immunocytokine L19-IL2 (watch our animation explaining the concept at https://youtu.be/6wDE6RkrikA). Palliative treatment is the current standard of care for patients with metastatic non small cell lung cancer (NSCLC), unless there is an actionable mutation. By using the concept of limited metastatic disease (≤10 sites, WHO 0-1: “oligo+”) we aim to develop a therapy with curative intent. IMMUNOSABR will gather evidence for the clinical efficacy of our bi-modal treatment strategy in a multicentre randomised phase II study (clinicaltrials.gov no. NCT02735850) in patients with limited metastatic NSCLC. IMMUNOSABR is complemented by two strong biomarker work packages which focus on developing an ambitious personalised biomarker strategy, to identify patients who can benefit from the novel treatment strategy. This includes promising non-invasive imaging techniques and state-of-the-art immunological monitoring approaches on tumour tissue and blood. IMMUNOSABR will spur further development of L19-IL2 as a commercial drug and translate the bi-modal treatment strategy towards clinical implementation.
| ACADEMISCH ZIEKENHUIS MAASTRICHT | 181 675 € |
| Centre Oscar Lambret | 115 175 € |
| CLINICAL TRIAL CENTER MAASTRICHT | 0,00 € |
| Cliniques Universitaires Saint-LUC ASBL | 115 175 € |
| Comunicare Solutions | 0,00 € |
| Danmarks Tekniske Universitet | 774 120 € |
| EBERHARD KARLS UNIVERSITAET TUEBINGEN | 165 050 € |
| European Cancer Patient Coalition | 25 761 € |
| EXOMNIS BIOTECH | 0,00 € |
| HEALTH INNOVATION VENTURES B.V. | 740 500 € |
| Katholieke Universiteit Leuven | 165 050 € |
| Philogen S.p.A. | 726 250 € |
| PT THERAGNOSTIC B.V. | 6 250,00 € |
| STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS | 115 175 € |
| STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRUM | 115 175 € |
| STICHTING RADBOUD UNIVERSITEIT | 0,00 € |
| TECHNISCHE UNIVERSITAET DRESDEN | 115 175 € |
| Universita Cattolica Del Sacro Cuore | 115 175 € |
| Universiteit Gent | 115 175 € |
| UNIVERSITEIT MAASTRICHT | 2 288 121 € |
| University College London | 115 175 € |
https://cordis.europa.eu/project/id/733008
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.